41 results about "Hyperphosphoremia" patented technology

The present invention provides novel type IIc Na/Pi cotransporters. These cotransporters are important Pi transporters that are highly expressed during the growth period from the weaning stage to the adult stage. Furthermore, the present invention provides FGF23 and mutants thereof as factors that regulate the expression of type II Na/Pi cotransporters. FGF23 suppresses Pi reabsorption through suppression of type II Na/Pi cotransporter expression in kidneys. Therefore, FGF23 can be used as a target substance for regulating Pi reabsorption in kidneys. The present invention provides important factors for the development of preventive and therapeutic agents for hyperphosphatemia or hypophosphatemia.

The present invention provides medicaments useful for reducing phosphorus serum level, especially in those subjects affected from hyperphosphatemia. More specifically, the present invention relates to pharmaceutical compositions to be administered by oral route in fasting periods, in order to absorb phosphorus compounds from fluids of the enteric tract, especially from saliva.

The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.

The invention provides low-phosphorus whey protein powder suitable for patients with chronic nephrosis. After the technical scheme is adopted, a brand new protein powder formula is designed aiming at the constitutional characteristics of the patients with the chronic nephrosis, so that the contents of phosphorus and potassium elements in a protein source are improved on one hand, and appropriate microelements are matched for the situation of nutritional disorder of the patient with the chronic nephrosis and especially for patients accepting dialysis therapy on the other hand; the low-phosphorus whey protein powder aims at avoiding the occurrence of hyperphosphatemia on the basis of replenishing high quality protein for the patients with the nephrosis, and improves the nutritional status of the patients with the nephrosis and promotes the physical recovery of the patients with the nephrosis at the same time. The product provided by the invention can help to improve the tolerance of the patients during treatment, reduce morbidity and mortality, improve the living quality of the patients, and the like. On this basis, a preparation method of the low-phosphorus whey protein powder is designed according to the characteristics of the formula materials; the method is carried out in a way of dry blending, and reduces the energy consumption by limiting the feeding sequence and the feeding amount; the obtained product is light in weight, good in water solubility and complete in nutrient retention.

A method for reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia is disclosed. The method includes the step of administering orally to the subject an anti-intestinal sodium phosphate cotransporter type 2B (Npt2B) antibody in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

The invention relates to novel medicinal application of medical carbon, in particular to the application of the medicinal carbon in the preparation of medicaments for curing hyperphosphatemia. In the invention, clinical tests prove that the medicinal carbon, when taken orally, can reduce the serium inorganic phosphorus level and the product of calcium and phosphorus of patients who have received hemodialysis and peritoneal dialysis but do not have the hyperphosphatemia controlled after receiving the treatment by the calcium-containing phosphate binder, and provides a voltage detection (VD) therapy opportunity for patients with secondary hyperparathyroidism which cannot be treated by the VD therapy because of over-high product of calcium and phosphorus. The medical carbon is favorable for reducing and preventing angiocardiopathy development death, caused by chronic kidney disease-mineral and bone disorder (CKD-MBD), of the dialysis patients. Thus, the medicinal carbon can be used as novel medicaments for curing the hyperphosphatemia of patients with dialysis.

The invention discloses a method for preparing lanthanum carbonate by reacting supercritical carbon dioxide and lanthanum oxide, which comprises the following steps: filling 50-99.999 wt% lanthanum oxide rare-earth raw material which has passed a 10-200-mesh sieve into an extraction kettle of a supercritical carbon dioxide extraction instrument, and reacting for 1-24 hours to obtain the lanthanum carbonate in the extraction kettle, wherein in the reaction process, the temperature of the extraction kettle is controlled at 32-100 DEG C, the pressure is 7.5-50 MPa, and the carbon dioxide with the mass percent of higher than 99.5% is subjected to forced circulation. The method is simple to operate, and has the advantages of no byproduct, low cost, high product purity and no environmental pollution. The lanthanum carbonate is a novel medicine for treating hyperphosphatemia, and has wide market prospects.

The invention discloses a method for preparing lanthanum carbonate by reacting subcritical carbon dioxide and lanthanum oxide, which comprises the following steps: filling 80-99.999 wt% lanthanum oxide rare-earth raw material which has passed a 40-300-mesh sieve into a reaction kettle, and reacting for 20-60 hours to obtain the lanthanum carbonate in the reaction kettle, wherein in the reaction process, the temperature of the extraction kettle is controlled at 25-31 DEG C, the pressure is 5-7.4 MPa, and the carbon dioxide with the mass percent of higher than 99.5% is subjected to forced circulation. The method is simple to operate, and has the advantages of no byproduct, low cost, high product purity and no environmental pollution. The lanthanum carbonate is a novel medicine for treating hyperphosphatemia, and has wide market prospects.

The invention provides a composition with the effect of preventing and treating complications of a dialysis patient, and a preparation method and application of the composition. The composition is prepared from the components in parts by mass: 5-33 parts of whey proteins, 1-20 parts of casein or salts of the casein, 1-50 parts of maltodextrin, 1-10 parts of corn syrup and 5-75 parts of sunflower seed oil. The blood potassium level can be controlled to be lower than 5.0 mmol/L, the blood phosphorus level is controlled to be lower than 1.78 mmol/L, the complications such as protein malnutrition,hyperphosphatemia, hyperkalemia and hypertension of the dialysis patient are comprehensively relieved, the dialysis interval time of the dialysis patient is prolonged, and the harm of dialysis to thebody is reduced. In addition, the composition in each unit dose is brewed with 60 mL of water, the liquid intake burden is relieved and is equivalent to the osmotic pressure of the human body, gastrointestinal tolerance is better, and patient compliance is higher.

The present invention relates to polycarbophil coated crosslinked amine polymers and/or pharmaceutical compositions comprising polycarbophil coated crosslinked amine polymers. The polycarbophil coated crosslinked amine polymers have several therapeutic applications, including, but not limited to, hyperphosphatemia, chronic kidney disease and End-Stage Renal Disease.

The invention relates to medicine treating hyperphospheremia and iron deficiency anemia. Polystyrene sulfoacid ferrous iron resin is used as the effective component of the medicine, the medicine is produced by either adding medical auxiliary material or not, administration is performed by passing through gastrointestinal tract, the effective component and phosphate in the alimentary tract of a patient are combined together to be an insoluble substance which is excreted to the outside of the body through the alimentary tract, thereby the phosphate in the body of a chronic renal failure patient is reduced, and the aim of treating the hyperphospheremia is achieved. Simultaneously, residual ferrous ions of the polystyrene sulfoacid ferrous iron resin are dissociated, and are absorbed by the human body to supplement the ferrous ions in the body, thereby achieving the aim of treating the iron deficiency anemia of the chronic renal failure patient. The medicine can also be used for the treatment of the hyperphospheremia of the chronic renal failure patient and used as the preventive agent of the iron deficiency anemia.

The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or lanthanum hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The capsules of the present invention dissolve at a similar rate before and after storage. The oral pharmaceutical capsules of the present invention can be administered to treat a patient at risk for or suffering from hyperphosphatemia, at risk for or suffering from chronic kidney disease (CKD), at risk for or suffering from soft tissue calcification associated with CKD, or at risk for or suffering from secondary hyperparathyroidism.

The invention provides a nutrition conveying method of a low-protein type total nutrient. According to the method for conveying the nutrient according to the intestinal gas amount of a microbiota, theintestinal gas amount of the microbiota related to a patient is monitored; the nutrient delivery amount delivered to the patient is controlled and/or the nutrient delivery rate is adjusted based on the relative change of the microbial community intestinal tract gas relative to the baseline value, so that the nutrient delivery is more scientific, and the absorption is more efficient. Besides, thelow-protein nutrient disclosed by the invention is scientific in formula, not only can reduce the intake of dietary protein to delay the loss of the residual kidney function of the patient, but also is beneficial to reducing the urine protein level of the patient and improving hyperphosphatemia, glycolipid metabolism and hypertension.

It is disclosed here a method for reducing phosphate absorption in a human or non-human animal subject wherein the subject consumes a diet containing phytic acid or phytate and either has or is at risk of developing hyperphosphatemia. The method includes the step of administering orally to the subject an anti-phytic acid (C₆H₆[OPO(OH)₂]_o) antibody or an anti-phytate antibody in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

A method of treating or inhibiting a kidney disorder can include administering a therapeutically effective amount of the ASARM peptide to provide a treatment for the kidney disorder (treat disease) and/or inhibit development of the kidney disorder (prophylactic). The kidney disorder can be selected from the group consisting of chronic kidney disease mineral bone disorder (CKD-MBD), calciphylaxis, nephrogenic systemic fibrosis (NSF), end stage renal disease, and combinations thereof. The therapy can include inhibiting vascular calcification (VC), hard tissue calcification, soft tissue calcification, mineralization, or combinations thereof in the subject with the ASARM peptide. A method of inhibiting mineralization can include administering a therapeutically effective amount of the ASARM peptide to provide a treatment for inhibit mineralization in the subject. A method of treating hyperphosphatemia can include administering a therapeutically effective amount of the ASARM peptide to a subject to provide a treatment for hyperphosphatemia.

The invention discloses an intestinal dialysis composition for pet dogs and cats and a preparation method of the intestinal dialysis composition and belongs to the field of veterinary care. The dialysis composition comprises the following components: 10-20g of unprocessed rehmannia roots, 10-20g of chitosan, 10-20g of calcium butyrate, 50-100g of modified zeolite and 200-300ml of acetic acid witha volume percentage of 4%. The preparation method comprises the following steps: sufficiently dissolving the unprocessed rehmannia roots, the chitosan and the calcium butyrate into the acetic acid, adding the modified zeolite, blending the components into a paste, performing sufficient infiltration, performing pelletizing by using a pelletizer, and performing drying at 60 DEG C for 4 hours, so asto obtain a finished product of which the particle size is 0.8-1.2mm. Components of the intestinal dialysis composition for pet dogs and cats take synergetic effects into play, uremia toxins such as urea and decomposition products, namely substances such as ammonia, phosphate and creatinine, of the uremia toxins, in intestines, can be adsorbed, small molecule substances such as the uremia toxins such as urea in blood can be promoted to be discharged to enterocoels, then the concentration of the small molecule substances in blood can be reduced, hyperazotemic and hyperphosphatemia caused by kidney failure can be relieved, and recovery of kidney failure can be facilitated. The composition is economic and practical and convenient to operate.

The invention provides a preparation method and application of a blood filtration displacement liquid containing organic phosphate. Sodium glycerophosphate is used as organic phosphate and has good mixing compatibility with a calcium-containing solution, and a sodium glycerophosphate injection is clinically used as an intravenous nutrition additive or a component of a mixed electrolyte solution. Sodium glycerophosphate is catalyzed by alkaline phosphatase in vivo and hydrolyzed into inorganic phosphate and glycerol which are metabolized and utilized by the organism. The sodium glycerophosphate injection can be used as a source of phosphorus-containing displacement liquid phosphate. The plasma phosphorus concentration is 1.0-1.5 mmol/L, but due to the fact that part of phosphorus is combined with plasma protein to form a compound, the filterable ionic state phosphorus concentration is actually 0.9-1.0 mmol/L. Therefore, in 2021, the replacement liquid with the phosphorus concentration being 0.7-1.0 mmol/L and the phosphorus concentration being 1.0 mmol/L recommended by China Standard Operation Regulations for Blood Purification can effectively prevent and treat the CRRT critical symptom hypophosphatemia, and the replacement liquid with the phosphorus concentration being 0.7-1.0 mmol/L and the phosphorus concentration being 1.0 mmol/L can be used for preventing and treating the CRRT critical symptom hypophosphatemia. Meanwhile, iatrogenic hyperphosphatemia is avoided as far as possible.

Disclosed are peptide-fatty acid conjugates, pharmaceutical compositions containing them, and methods of their medical use in the treatment of, e.g., a disease or condition associated with the PTHR1 signaling overactivity (e.g., hypercalcemia, hypophosphatemia, hyperparathyroidism, or Jansen's chondrodysplasia) or deficiency (e.g., hypoparathyroidism, hyperphosphatemia, osteoporosis, fracture repair, osteomalacia, arthritis, or thrombocytopenia).